Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study. Mayer EL, Smith ML, Guerin A, Latremouille-Viau D, et al. Breast Cancer Res Treat 2025 Feb 7. doi: 10.1007/s10549-025-07627.

Read + Share

Amedeo Smart

Independent Medical Education

Mayer EL, Smith ML, Guerin A, Latremouille-Viau D, et al. Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study. Breast Cancer Res Treat 2025 Feb 7. doi: 10.1007/s10549-025-07627.
PMID: 39915434